

REMARKS

The Examiner requires under 37 CFR 1.499 that Applicants elect a single invention from:

Group I, claims 1-11, which are drawn to a microparticle comprising a somatostatin analog comprising the amino acid sequence of formula I, -(D/L)Trp-Lys-X1-X2-

Group II, claim 13, drawn to a method of treating a disease or disorder with an etiology comprising or associated with excess of GH- and/or IGF-1 secretion in a subject in need thereof...

Without traverse, Applicants elect Group I.

Further the Examiner request an election of species for somatostatin analogs, polymer matrices, tonicity agent, viscosity increasing agent and porosity influencing agent.

Applicants elect the following:

somatostatin analog: compound of claim 2

polymer matrix: see Example 8

tonicity agent: Vehicle E (mannitol)

viscosity agent: Vehicle E (CMC-Na)


porosity agent: polyvinyl pyrrolidone

Claims 1-11 encompass the elected invention.

If the Examiner has questions please contact the undersigned attorney.

Respectfully submitted,

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Date: April 20, 2009